, ANGLAIS 11 BIOLOGIE CELLULAIRE 4403
,
,
,
,
, GYNECOLOGIE MEDICALE, p.5405
,
,
, BIOPHYSIQUE ET MEDECINE NUCLEAIRE, vol.4301, p.5102
,
,
,
,
,
, 69ème section) FRAISSE Alain (PU-PH) Disponibilité, BELIN Pascal (PR)
PR) (69ème section) FRANCESCHI Frédéric (PU-PH) ,
,
,
, MCU-PH) THUNY Franck
MCF) (69ème section) CHIRURGIE DIGESTIVE 5202 ,
, BERDAH Stéphane (PU-PH)
, HARDWIGSEN Jean (PU-PH)
,
, PU-PH) Surnombre SIELEZNEFF Igor
,
,
,
, , p.5302
,
,
,
,
, TURRINI Olivier (PU-PH)
MCF) (5ème section) ,
MCF) (5ème section) BEGE Thierry (MCU-PH) ,
, Mis à jour 16, 2016.
, CHIRURGIE ORTHOPEDIQUE ET TRAUMATOLOGIQUE, vol.5002
,
, BLONDEL Benjamin (PU-PH)
, CURVALE Georges (PU-PH)
, ALESSANDRINI Pierre (PU-PH) Surnombre
,
,
,
,
,
, CANCEROLOGIE, p.4702
, , p.5503
, CHINOT Olivier (PU-PH)
,
,
, GONCALVES Anthony PU-PH)
, HOUVENAEGHEL Gilles (PU-PH)
, MARANINCHI Dominique (PU-PH) Surnombre
, SALAS Sébastien (PU-PH)
, VIENS Patrice (PU-PH)
, SABATIER Renaud (MCU-PH)
, , p.5004
, COLLART Frédéric (PU-PH)
,
,
, GARIBOLDI Vlad (PU-PH)
,
, THOMAS Pascal (PU-PH)
,
, GRISOLI Dominique (MCU-PH)
, TROUSSE Delphine (MCU-PH)
, CHIRURGIE
, ALIMI Yves (PU-PH)
,
,
,
,
,
,
, LAUGIER René (PU-PH)
,
, VITTON Véronique (PU-PH)
,
, LEPIDI Hubert (PU-PH)
,
,
, Mis à jour 16, 2016.
, GENETIQUE 4704 DERMATOLOGIE -VENEREOLOGIE 5003 BEROUD Christophe
,
,
,
,
, NGYUEN Karine (MCU-PH)
, TOGA Caroline (MCU-PH)
,
, GYNECOLOGIE MEDICALE, vol.5404
, BRUE Thierry (PU-PH)
, CASTINETTI Frédéric (PU-PH)
,
, GYNECOLOGIE, p.5403
,
,
,
,
,
,
, THIRION Xavier (PU-PH)
,
, BERBIS Julie (MCU-PH)
,
, MINVIELLE/DEVICTOR Bénédicte (MCF)
,
,
,
,
,
,
, FERON François (PR) (69ème section) VEY Norbert
,
,
,
,
,
, VELY Frédéric (MCU-PH)
,
MCF) 65ème section) (retraite octobre, 2016. ,
, POGGI Marjorie (MCF)
MCF) 65ème section) ,
, Mis à jour 16, 2016.
, , p.4603
, LEONETTI Georges (PU-PH)
,
,
,
, PAROLA Philippe (PU-PH)
, STEIN Andréas (PU-PH)
MCF) (1ère section) ,
,
, , p.4905
, MEDECINE
,
,
,
,
, , p.4602
,
,
,
,
, EBBO Mikael (MCU-PH)
, GENTILE Gaëtan (MCF Méd. Gén. Temps plein) NEPHROLOGIE, vol.5203
Gén. à mi-temps) BERLAND Yvon (PU-PH) ,
, BRUNET Philippe (PU-PH)
Gén. à mi-temps) BURTEY Stépahne (PU-PH) ,
, BARGIER Jacques (MCF associé Méd. Gén. À mi-temps) DUSSOL Bertrand
Gén à mi-temps) MOAL Valérie (PU-PH) ,
,
Gén. à mi-temps) JOURDE CHICHE Noémie (MCU PH) ,
,
,
,
,
, SCAVARDA Didier (PU-PH)
, ATLAN Catherine (MCU-PH)
, MARANINCHI Marie (MCF)
, Mis à jour 16, 2016.
, NEUROLOGIEBIOLOGIE CELLULAIRE), vol.4901, issue.65
, PR) (66ème section) AUDOIN Bertrand
, SOBOL Hagay (PR) (65ème section) AZULAY Jean-Philippe (PU-PH) CECCALDI Mathieu
, EUSEBIO Alexandre (PU-PH)
, OPHTALMOLOGIE, vol.5502
,
,
, HOFFART Louis (PU-PH)
, MATONTI Frédéric (PU-PH)
, RIDINGS Bernard (PU-PH) Surnombre PEDOPSYCHIATRIE, p.4904
,
, POINSO François (PU-PH)
, OTO-RHINO-LARYNGOLOGIE 5501
, PHARMACOLOGIE FONDAMENTALE
, , p.4803
, FAKHRY Nicolas (PU-PH)
,
,
,
,
,
,
Professeur associé des universités mi-temps) PHILOSPHIE 17 ,
, , p.4502
PR) (17ème section) ,
, DESSEIN Alain (PU-PH)
, PIARROUX Renaud (PU-PH)
, ALTAVILLA Annagrazia (PR Associé à mi-temps)
, CASSAGNE Carole (MCU-PH)
,
, MARY Charles (MCU-PH)
, RANQUE Stéphane (MCU-PH)
, TOGA Isabelle (MCU-PH) PEDIATRIE 5401 PHYSIOLOGIE 4402
,
,
,
, MILH Mathieu (PU-PH)
,
, REYNAUD Rachel (PU-PH)
,
,
,
, Bibliographie
Refractory Sideroblastic Anemia Secondary to Autoimmune Hemolytic Anemia, Acta Haematologica, vol.58, issue.4, p.2136, 1977. ,
DOI : 10.1159/000207830
Myelodysplastic syndromes and autoimmune diseases???Case series and review of literature, Leukemia Research, vol.37, issue.8, pp.894-903, 2013. ,
DOI : 10.1016/j.leukres.2013.04.007
URL : http://europepmc.org/articles/pmc3699612?pdf=render
Risks of myeloid malignancies in patients with autoimmune conditions, British Journal of Cancer, vol.59, issue.5, pp.822-830, 2009. ,
DOI : 10.1001/archinte.165.20.2337
Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the General Practice Research Database, Cancer Epidemiology, vol.38, issue.5, pp.544-553, 2014. ,
DOI : 10.1016/j.canep.2014.08.003
Chronic Immune Stimulation Might Act As a Trigger for the Development of Acute Myeloid Leukemia or Myelodysplastic Syndromes, Journal of Clinical Oncology, vol.29, issue.21, pp.2897-903, 2011. ,
DOI : 10.1200/JCO.2011.34.8540
,
Immunological abnormalities in myelodysplastic syndromes Prospective study (series of 40 patients) Rev Med Interne, pp.777-83, 2005. ,
Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients, International Journal of Hematology, vol.66, pp.345-351, 1997. ,
DOI : 10.1016/S0925-5710(97)00042-X
, HAS) : Guide du parcours de soins : Insuffisances médullaires et autres cytopénies chroniques, 2015.
Proposals for the classification of the myelodysplastic syndromes, British Journal of Haematology, vol.92, issue.2, p.189, 1982. ,
DOI : 10.1016/0145-2126(79)90006-7
The World Health Organization (WHO) classification of the myeloid neoplasms, Blood, vol.100, issue.7, pp.2292-302, 2002. ,
DOI : 10.1182/blood-2002-04-1199
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood, vol.114, issue.5, pp.937-51, 2009. ,
DOI : 10.1182/blood-2009-03-209262
The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia, Blood, 2016. ,
International scoring system for evaluating prognosis in myelodysplastic syndromes, Blood, vol.89, pp.2079-88, 1997. ,
DOI : 10.1182/blood-2012-03-420489
URL : http://www.bloodjournal.org/content/120/12/2454.full.pdf
,
, Revised international prognostic scoring system for myelodysplastic syndromes
, Blood, vol.120, issue.12, pp.2454-65, 2012.
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia, Blood, vol.108, issue.2, 2006. ,
DOI : 10.1182/blood-2005-10-4149
, Jul Epub, vol.15108, issue.2, pp.419-444, 2006.
Autologous lymphocytes inhibit hemopoiesis in long-term culture in patients with myelodysplastic syndrome, Experimental Hematology, vol.30, issue.12, pp.1405-1416, 2002. ,
DOI : 10.1016/S0301-472X(02)00968-2
Interferon-??-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles, Blood, vol.107, issue.1, pp.167-75, 2006. ,
DOI : 10.1182/blood-2005-05-1884
Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro, Blood, vol.85, issue.11, pp.3183-90, 1995. ,
In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis, Blood, vol.99, issue.5, pp.1594-601, 2002. ,
DOI : 10.1182/blood.V99.5.1594
Effects of thalidomide on long-term bone marrow cultures from patients with myelodysplastic syndromes: Induction of IL-10 expression in the stromal layers, Leukemia Research, vol.35, issue.8, pp.1102-1109, 2011. ,
DOI : 10.1016/j.leukres.2011.03.027
Inhibition of the TGF-?? receptor I kinase promotes hematopoiesis in MDS, Blood, vol.112, issue.8, pp.3434-3477, 2008. ,
DOI : 10.1182/blood-2008-02-139824
Autoimmune manifestations in human myelodysplasia: a positive correlation with interferon regulatory factor-1 (IRF-1) expression, Annals of the Rheumatic Diseases, vol.63, issue.5, pp.578-82, 2004. ,
DOI : 10.1136/ard.2003.012948
URL : https://ard.bmj.com/content/63/5/578.full.pdf
CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS), Blood, vol.110, issue.3, pp.847-50, 2007. ,
DOI : 10.1182/blood-2007-01-067546
URL : http://www.bloodjournal.org/content/110/3/847.full.pdf
Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): Cause or consequence?, Best Practice & Research Clinical Haematology, vol.26, issue.4, pp.327-363, 2013. ,
DOI : 10.1016/j.beha.2013.09.003
T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome, British Journal of Haematology, vol.164, issue.Suppl. 3, pp.64-72, 2009. ,
DOI : 10.4049/jimmunol.164.5.2832
URL : https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2141.2009.07593.x
Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS), Leukemia, vol.172, issue.3, pp.510-518, 2009. ,
DOI : 10.1038/nri2138
,
, Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes, Haematologica, vol.93, pp.381-390, 2008.
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides, Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides, pp.1-11, 2012. ,
DOI : 10.1097/BOR.0b013e3283412f7c
URL : https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.37715
Vasculitides and cancers: 60 cases, Arthritis Rheum, vol.50, p.436, 2004. ,
Value of infliximab (Remicade(R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group, Haematologica, vol.97, issue.4, pp.529-562, 2012. ,
DOI : 10.3324/haematol.2011.044347
Sweet's syndrome and malignancy, The American Journal of Medicine, vol.82, issue.6, pp.1220-1226, 1987. ,
DOI : 10.1016/0002-9343(87)90229-4
Sweet's syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease, British Journal of Haematology, vol.76, issue.2, pp.356-364, 1993. ,
DOI : 10.7326/0003-4819-116-12-996
Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome, Annals of the Rheumatic Diseases, vol.67, issue.2, pp.278-287, 2008. ,
DOI : 10.1136/ard.2006.068254
Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group, Annals of the Rheumatic Diseases, vol.61, issue.6, pp.554-562, 2002. ,
DOI : 10.1136/ard.61.6.554
Immunohematological Findings in Myelodysplastic Syndrome, Acta Haematologica, vol.105, issue.1, pp.1-6, 2001. ,
DOI : 10.1159/000046525
Cyclosporine A in the Treatment of a Patient with Immune Thrombocytopenia Accompanied by Myelodysplastic Syndrome and Nephrotic Syndrome, Acta Haematologica, vol.110, issue.1, pp.36-40, 2003. ,
DOI : 10.1159/000072413
Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study, Rheumatology, vol.39, issue.2, p.291300, 2016. ,
DOI : 10.1007/s12185-013-1316-x
URL : https://hal.archives-ouvertes.fr/hal-01299293
Autoimmune diseases and myelodysplastic syndromes, American Journal of Hematology, vol.99, issue.5, pp.280-283, 2016. ,
DOI : 10.3324/haematol.2012.083345
URL : http://onlinelibrary.wiley.com/doi/10.1002/ajh.24333/pdf
Certain Autoimmune Manifestations Are Associated With Distinctive Karyotypes and Outcomes in Patients With Myelodysplastic Syndrome, Medicine, vol.95, issue.13, p.3091, 2016. ,
DOI : 10.1097/MD.0000000000003091
URL : http://pdfs.journals.lww.com/md-journal/2016/03290/Certain_Autoimmune_Manifestations_Are_Associated.6.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1504182317825;payload|mY8D3u1TCCsNvP5E421JYK6N6XICDamxByyYpaNzk7FKjTaa1Yz22MivkHZqjGP4kdS2v0J76WGAnHACH69s21Csk0OpQi3YbjEMdSoz2UhVybFqQxA7lKwSUlA502zQZr96TQRwhVlocEp/sJ586aVbcBFlltKNKo+tbuMfL73hiPqJliudqs17cHeLcLbV/CqjlP3IO0jGHlHQtJWcICDdAyGJMnpi6RlbEJaRheGeh5z5uvqz3FLHgPKVXJzddFRrD2hcIwdDP9eSnSkfs1F10o5ZJ6tSDqMjjaCTucs=;hash|e1QmPlQKDyPQQUjO8t3Vng==
Inflammatory Arthritis in Patients With Myelodysplastic Syndromes, Medicine, vol.93, issue.1, pp.1-10, 2014. ,
DOI : 10.1097/MD.0000000000000011
URL : https://hal.archives-ouvertes.fr/hal-01064616
,
, Low C3 levels is associated with neutropenia in a proportion of patients with myelodysplastic syndrome: retrospective analysis, International Journal of Rheumatic Diseases, vol.15, pp.86-94, 2012.
Systemic and immune manifestations in myelodysplasia: A multicenter retrospective study, Arthritis Care & Research, vol.63, issue.8, p.11881194, 2011. ,
DOI : 10.1136/ard.2003.012948
Risks of myeloid malignancies in patients with autoimmune conditions, British Journal of Cancer, vol.59, issue.5, p.822828, 2009. ,
DOI : 10.1001/archinte.165.20.2337
Cutaneous manifestations in relation to immunologic parameters in a cohort of primary myelodysplastic syndrome patients, Journal of the European Academy of Dermatology and Venereology, vol.55, issue.5, pp.543-548, 2008. ,
DOI : 10.1016/S0925-5710(97)00042-X
Immunologic Abnormalities in Myelodysplastic Syndromes: Clinical Features and Characteristics of the Lymphoid Population, Medical Oncology, vol.23, issue.3, p.385391, 2006. ,
DOI : 10.1385/MO:23:3:385
,
, Autoimmune phenomena in myelodysplastic syndromes: a 4yr prospective study
, Rheumatology (Oxford), vol.43, issue.5, p.626632, 2004.
,
, Myélodysplasies et maladies systémiques : une association non fortuite, Rev Med Interne, vol.22, pp.428-432, 2001.
,
, Prevalence of rheumatic manifestations and antineutrophil cytoplasmic antibodies in haematological malignancies. A prospective study, Rheumatology (Oxford), vol.39, issue.4, pp.417-437, 2000.
Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy, British Journal of Haematology, vol.9, issue.2, p.403408, 1995. ,
DOI : 10.1002/ajh.2830240112
Immunemediated complications in patients with myelodysplastic syndromes: clinical and cytogenetic features, Eur J Haematol, vol.55, issue.1, p.4248, 1995. ,
Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia, Leukemia Research, vol.43, pp.4313-4330, 2016. ,
DOI : 10.1016/j.leukres.2016.02.005
URL : https://hal.archives-ouvertes.fr/hal-01278608
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML), Blood, vol.119, issue.14, pp.3361-3370, 2012. ,
DOI : 10.1182/blood-2011-09-377044
,
, Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5azacytidine and literature review, Eur J Haematol, vol.93, pp.247-59, 2014.
Regulation of the Interleukin-6 gene expression during monocytic differentiation of HL-60 cells by chromatin remodeling and methylation, Immunobiology, vol.219, issue.8, pp.619-645, 2014. ,
DOI : 10.1016/j.imbio.2014.03.016
The evolving challenge of therapy-related myeloid neoplasms, Best Practice & Research Clinical Haematology, vol.26, issue.4, pp.309-326, 2013. ,
DOI : 10.1016/j.beha.2013.09.001
Azathioprine: Association with Therapy-related Myelodysplastic Syndrome and Acute Myeloid Leukemia, The Journal of Rheumatology, vol.37, issue.3, pp.485-90, 2010. ,
DOI : 10.3899/jrheum.090834
Cytogenetic abnormalities and therapy-related myelodysplastic syndromes in rheumatic disease, Arthritis & Rheumatism, vol.88, issue.8, pp.1493-1499, 1998. ,
DOI : 10.1073/pnas.88.14.6176
,
, Au moment d'être admis(e) à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité
, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux
, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité, Je respecterai toutes les personnes Même sous la contrainte, je ne ferai pas usage de mes connaissances contre les lois de l'humanité
, J'informerai les patients des décisions envisagées, de leurs raisons et de leurs conséquences
, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences
, Je donnerai mes soins à l'indigent et à quiconque me les demandera Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire
, Admis(e) dans l'intimité des personnes, je tairai les secrets qui me seront confiés Reçu(e) à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs
, Je ferai tout pour soulager les souffrances Je ne prolongerai pas abusivement les agonies
, Je ne provoquerai jamais la mort délibérément
, Je préserverai l'indépendance nécessaire à l'accomplissement de ma mission Je n'entreprendrai rien qui dépasse mes compétences, Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés
, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité
, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses ; que je sois déshonoré(e) et méprisé(e) si j'y manque